Search results for "Lymphatic"

showing 10 items of 1179 documents

PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery

2013

Abstract Salmon calcitonin (sCT) is characterized by a poor oral availability. A new copolymer, β-poly(N-2-hydroxyethyl)-graft-{N-2-ethylene[2-poly(methacrylic acid sodium salt)isobutyrate]}- d , l -aspartamide (PHEA-IB-p(MANa + )), was designed for the oral administration of sCT through the formation of supramolecular aggregates (SAs) based on electrostatic interactions. Several sCT/PHEA-IB-p(MANa + ) weight ratios were characterized by turbidimetry, DLS, zeta potential, and microscopy analysis. After the incubation of sCT/PHEA-IB-p(MANa + ) complex with digestive enzymes, 10% (w/w) of loaded sCT was released in the native form. In vitro investigation was carried out to determine the copol…

Calcitoninmedicine.medical_specialtypeptide deliveryAdministration OralPharmaceutical Sciencechemistry.chemical_elementPeptidePharmacologyCalciumRats Sprague-DawleyRandom AllocationDrug Delivery SystemsPolymethacrylic AcidsPharmacokineticsimmune system diseasesOral administrationhemic and lymphatic diseasesmedicineAnimalsHumansPolyhydroxyethyl Methacrylatechemistry.chemical_classificationDrug CarriersGeneral Medicineoral deliveryRatsBioavailabilitySurgeryoral delivery; peptide delivery; calcitoninsurgical procedures operativechemistryCalcitoninSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPharmacodynamicsFemaleTurbidimetryCaco-2 CellsPeptidestherapeuticshuman activitiesPHEA oral delivery osteoporosis supramolecolar aggregates peptide almon calcitoninBiotechnology
researchProduct

Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis

2012

The present study is designed to assess if exosomes released from Chronic Myelogenous Leukemia (CML) cells may modulate angiogenesis. We have isolated and characterized the exosomes generated from LAMA84 CML cells and demonstrated that addition of exosomes to human vascular endothelial cells (HUVEC) induces an increase of both ICAM-1 and VCAM-1 cell adhesion molecules and interleukin-8 expression. The stimulation of cell-cell adhesion molecules was paralleled by a dose-dependent increase of adhesion of CML cells to a HUVEC monolayer. We further showed that the treatment with exosomes from CML cells caused an increase in endothelial cell motility accompanied by a loss of VE-cadherin and β-ca…

Cancer ResearchAngiogenesisVascular Cell Adhesion Molecule-1BiologyExosomesArticleExosomes Chronic Myelogenous Leukemia Cells Endothelial cells Tumor MicroenvironmentMiceAntigens CDCell Movementhemic and lymphatic diseasesCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCell AdhesionHuman Umbilical Vein Endothelial CellsTumor MicroenvironmentAnimalsHumansCell adhesionbeta CateninMatrigelTumor microenvironmentNeovascularization PathologicCell adhesion moleculeInterleukin-8medicine.diseaseCadherinsIntercellular Adhesion Molecule-1MicrovesiclesCell biologyEndothelial stem cellDrug CombinationsOncologyGene Expression RegulationCancer researchProteoglycansCollagenLamininChronic myelogenous leukemia
researchProduct

Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells

1996

4-Demethoxydaunorubicin (idarubicin, IDA) is an anthracycline that has shown good cytotoxic activity in vitro against tumor cell lines displaying the multidrug-resistant (MDR) phenotype. IDA is converted in the liver into idarubicinol (2HIDA) and, in this form, seems to exert its antitumoral activity in vivo. Recent studies have shown that 2HIDA has tumoricidal activity similar to that of the parent drug when tested in vitro in sensitive neoplastic cells. In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562. IDA and 2HI…

Cancer ResearchAnthracyclineAntineoplastic AgentsPharmacologyBiologyToxicologyIn vivohemic and lymphatic diseasesCyclosporin aAntineoplastic Combined Chemotherapy ProtocolsTumor Cells CulturedmedicineCytotoxic T cellIdarubicinPharmacology (medical)PharmacologyAntibiotics AntineoplasticDaunorubicinnutritional and metabolic diseasesFlow CytometryDrug Resistance MultipleIn vitroMultiple drug resistanceOncologyCell cultureCyclosporineIdarubicinImmunosuppressive Agentsmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells

2010

MOZ and MLL, encoding a histone acetyltransferase (HAT) and a histone methyltransferase, respectively, are targets for recurrent chromosomal translocations found in acute myeloblastic or lymphoblastic leukemia. In MOZ (MOnocytic leukemia Zinc-finger protein)/CBP- or mixed lineage leukemia (MLL)-rearranged leukemias, abnormal levels of HOX transcription factors have been found to be critical for leukemogenesis. We show that MOZ and MLL cooperate to regulate these key genes in human cord blood CD34+ cells. These chromatin-modifying enzymes interact, colocalize and functionally cooperate, and both are recruited to multiple HOX promoters. We also found that WDR5, an adaptor protein essential fo…

Cancer ResearchAntigens CD34HistonesHistone H3hemic and lymphatic diseasesHistone methylationGeneticsHumansWDR5Tissue DistributionPromoter Regions GeneticHox geneneoplasmsMolecular BiologyCells CulturedHistone AcetyltransferasesHomeodomain ProteinsGeneticsBlood CellsbiologyIntracellular Signaling Peptides and ProteinsHistone-Lysine N-MethyltransferaseReceptor Cross-TalkU937 CellsHistone acetyltransferaseFetal BloodHematopoiesisCell biologyGene Expression RegulationHistone methyltransferasebiology.proteinMyeloid-Lymphoid Leukemia ProteinH3K4me3K562 CellsMyeloid-Lymphoid Leukemia ProteinProtein BindingOncogene
researchProduct

Genetic evolution of T-cell resistance in the course of melanoma progression

2014

Abstract Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell–stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alteratio…

Cancer ResearchB7 Antigensmedicine.medical_treatmentMedizinGene ExpressionT-Lymphocyte Subsetshemic and lymphatic diseasesCluster AnalysisLymphocytesNeoplasm MetastasisLymph nodeMelanomaTumorImmunogenicityMelanomaSingle Nucleotidemedicine.anatomical_structurePhenotypeButorphanolOncologyDisease ProgressionCytokinesEvolutionT cellHuman leukocyte antigenBiologyPolymorphism Single NucleotideArticleCell LineEvolution MolecularLymphocytes Tumor-InfiltratingCell Line TumormedicineHumansGenetic Predisposition to DiseaseTumor-InfiltratingAllelePolymorphismneoplasmsAllelesNeoplasm StagingHistocompatibility Antigens Class IMolecularImmunotherapymedicine.diseaseAlleles; B7 Antigens; Butorphanol; Cell Line Tumor; Cluster Analysis; Cytokines; Disease Progression; Gene Expression; Genetic Predisposition to Disease; Histocompatibility Antigens Class I; Humans; Lymphocytes Tumor-Infiltrating; Melanoma; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phenotype; Polymorphism Single Nucleotide; T-Lymphocyte Subsets; beta 2-Microglobulin; Evolution Molecular; Oncology; Cancer ResearchImmunologyMutationbeta 2-MicroglobulinCD8
researchProduct

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

2015

Recent data suggest that constitutional genetic variation in the antiapoptotic BCL2 gene could be associated with the susceptibility to develop chronic myeloid leukemia (CML) and the clinical outcome in several hematological malignancies. The present study examines whether BCL2 single nucleotide polymorphisms (SNPs) predispose to CML or may potentially influence the disease characteristics at diagnosis. Notably, no association was observed between the four candidate BCL2 SNPs and the risk of developing CML. Instead, the 4777C>A (rs2279115) and the 5735A>G (rs1801018) SNPs were significantly associated with the disease risk profile as determined by the Sokal score. We found that such polymor…

Cancer ResearchBCL2business.industryAlternative splicingChronic myeloid leukemiaClinical courseMyeloid leukemiaSingle-nucleotide polymorphismHematologyBioinformaticsSplicingBCL2 Chronic myeloid leukemia Polymorphisms Splicing SusceptibilityOncologyimmune system diseasesSusceptibilityhemic and lymphatic diseasesGenetic variationRNA splicingMedicinebiological phenomena cell phenomena and immunitySokal ScorebusinessPolymorphismsGeneneoplasms
researchProduct

A new pericentric inv(8) in acute nonlymphocytic leukemia.

1993

Abstract Chromosome studies were carried out on unstimulated bone marrow cells from a patient with a diagnosis of acute nonlymphocytic leukemia (FAB M6 ANLL). Cytogenetic analysis revealed a mosaic chromosome pattern 46,XX46,XX,inv(8)(p21q24). This pericentric inversion has not been previously described in ANLL. Because, fragile sites, zinc finger gene loci, and the MYC protooncogene have been localized to band 8q24, a putative role for these sites and genes could be considered.

Cancer ResearchBiologychromosome Acute nonlymphocytic leukemia cytogeneticshemic and lymphatic diseasesGeneticsmedicineHumansMolecular BiologyGeneChromosomal inversionZinc fingerGeneticsChromosomal fragile siteChromosomeMiddle Agedmedicine.diseaseMolecular biologySettore BIO/18 - GeneticaLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureKaryotypingChromosome InversionFemaleBone marrowChromosomes Human Pair 8Cancer genetics and cytogenetics
researchProduct

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway

2009

In chronic myeloid leukemia, activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway is crucial for survival and proliferation of leukemic cells. Essential downstream molecules involve mammalian target of rapamycin (mTOR) and S6-kinase. Here, we present a comprehensive analysis of the molecular events involved in activation of these key signaling pathways. We provide evidence for a previously unrecognized phospholipase C-gamma1 (PLC-gamma1)-controlled mechanism of mTOR/p70S6-kinase activation, which operates in parallel to the classical Akt-dependent machinery. Short-term imatinib treatment of Bcr-Abl-positive cells caused dephosphorylation of p70S6-K and S6-protein without inactivat…

Cancer ResearchBlotting WesternMedizinFusion Proteins bcr-ablApoptosisProtein Serine-Threonine KinasesBiologyPiperazinesMiceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesGeneticsAnimalsHumansRNA Small InterferingProtein Kinase InhibitorsMolecular BiologyProtein kinase BCAMKPI3K/AKT/mTOR pathwayPhospholipase C gammaCell growthKinaseTOR Serine-Threonine KinasesRPTORIntracellular Signaling Peptides and ProteinsRibosomal Protein S6 Kinases 70-kDaCell biologyEnzyme ActivationPyrimidinesBenzamidesembryonic structuresImatinib MesylateCancer researchPhosphorylationSignal transductionProto-Oncogene Proteins c-aktSignal TransductionOncogene
researchProduct

Release of IFNγ by Acute Myeloid Leukemia Cells Remodels Bone Marrow Immune Microenvironment by Inducing Regulatory T Cells

2022

Abstract Purpose: The stromal and immune bone marrow (BM) landscape is emerging as a crucial determinant for acute myeloid leukemia (AML). Regulatory T cells (Treg) are enriched in the AML microenvironment, but the underlying mechanisms are poorly elucidated. Here, we addressed the effect of IFNγ released by AML cells in BM Treg induction and its impact on AML prognosis. Experimental Design: BM aspirates from patients with AML were subdivided according to IFNG expression. Gene expression profiles in INFγhigh and IFNγlow samples were compared by microarray and NanoString analysis and used to compute a prognostic index. The IFNγ release effect on the BM microenvironment was investigated in me…

Cancer ResearchBone Marrow CellsMesenchymal Stem CellsSettore MED/08 - Anatomia PatologicaT-Lymphocytes RegulatoryInterferon-gammaLeukemia Myeloid AcuteMiceOncologyBone Marrowhemic and lymphatic diseasesTumor MicroenvironmentAnimalsIFNγ Acute Myeloid Leukemia Bone Marrow Immune Microenvironment
researchProduct

The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.

1992

The macrocyclic lactone bryostatin-1 was found to exert in vitro antineoplastic activity against several leukemic cell lines, including human K562 erythroleukemia, HL60 promyelocytic leukemia, REH and MOLT-4 lymphoblastic leukemias, CCRFCEM lymphoma, KG-1 myeloid leukemia, and murine P388 lymphocytic leukemia. No statistically significant difference in sensitivity to bryostatin-1 was found between adriamycin-resistant P388 and K526 subclones and their sensitive counterparts. Freshly explanted clonogenic leukemic cells showed a variable sensitivity to bryostatin-1 in 10/12 tested samples. The IC50 of clonogenic leukemic cells was 4 × 10–3 M bryostatin-1, and that of normal marrow CFU-GM was…

Cancer ResearchBryostatin 1LymphomaHL60Antineoplastic AgentsAntileukemic agent030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compoundLactones0302 clinical medicinehemic and lymphatic diseasesmedicineTumor Cells CulturedHumansClonogenic assayTumor Stem Cell AssayLeukemiaChemistryMyeloid leukemiaGeneral Medicinemedicine.diseaseBryostatinsHaematopoiesisLeukemiaOncology030220 oncology & carcinogenesisCancer researchMacrolidesDrug Screening Assays AntitumorK562 cellsTumori
researchProduct